FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

11 results

everolimus
(Everolimus)
ENDO USA, Inc.
Usage: Everolimus Tablets are indicated for postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer; adults with progressive neuroendocrine tumors (pancreatic, gastrointestinal, or lung origin); advanced renal cell carcinoma after prior treatment failure; renal angiomyolipoma associated with tuberous sclerosis complex; and subependymal giant cell astrocytoma in TSC patients.
fotivda
(Tivozanib)
AVEO Pharmaceuticals, Inc.
Usage: FOTIVDA is indicated for treating adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after two or more prior systemic therapies.
inlyta
(axitinib)
Pfizer Laboratories Div Pfizer Inc
Usage: INLYTA is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) in combination with avelumab or pembrolizumab. It is also indicated as a single agent for second-line treatment of advanced RCC following the failure of one prior systemic therapy.
inlyta
(axitinib)
U.S. Pharmaceuticals
Usage: INLYTA is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) in combination with avelumab or pembrolizumab. It is also indicated as a single agent for advanced RCC following the failure of one prior systemic therapy.
pazopanib
(pazopanib hydrochloride)
Novugen Pharma (USA) LLC.
Usage: Pazopanib tablets are indicated for adults with advanced renal cell carcinoma and advanced soft tissue sarcoma after prior chemotherapy. Efficacy for adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated.
pazopanib
(Pazopanib)
SUN PHARMACEUTICAL INDUSTRIES, INC.
Usage: Pazopanib tablets are indicated for the treatment of adults with advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy. Efficacy has not been established for adipocytic STS or gastrointestinal stromal tumors.
sorafenib
(Sorafenib)
Teva Pharmaceuticals Inc
Usage: Sorafenib tablets are indicated for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and locally recurrent or metastatic, progressive differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
sutent
(Sunitinib malate)
U.S. Pharmaceuticals
Usage: SUTENT is indicated for adult patients with gastrointestinal stromal tumor (GIST) post-imatinib treatment, advanced renal cell carcinoma (RCC), adjuvant therapy for high-risk recurrent RCC post-nephrectomy, and progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in unresectable or metastatic stages.
temsirolimus
(temsirolimus)
Accord Healthcare Inc.
Usage: Temsirolimus injection is indicated for the treatment of advanced renal cell carcinoma.
votrient
(pazopanib hydrochloride)
Novartis Pharmaceuticals Corporation
Usage: VOTRIENT® is indicated for treating adults with advanced renal cell carcinoma and advanced soft tissue sarcoma in those who have previously undergone chemotherapy. Its efficacy has not been established for adipocytic soft tissue sarcomas or gastrointestinal stromal tumors.

Medications for Renal Cell Carcinoma

everolimus

fotivda

inlyta

inlyta

pazopanib

pazopanib

sorafenib

sutent

temsirolimus

votrient